<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00912574</url>
  </required_header>
  <id_info>
    <org_study_id>8380</org_study_id>
    <nct_id>NCT00912574</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38</brief_title>
  <acronym>MEL38</acronym>
  <official_title>Evaluation of the Effects of Local GM-CSF-in-Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Goal: To characterize the cellular events that occur in vivo after vaccination with an&#xD;
      emulsion of GMCSF-in-adjuvant.&#xD;
&#xD;
      Design: Open-label, single dose study in two stages.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Regimen: Each injection will be administered to patients with clinical stage I or II&#xD;
      melanoma, who have had complete excision of a primary melanoma, but prior to wide excision&#xD;
      with or without sentinel node biopsy as definitive surgical therapy.&#xD;
&#xD;
      In Stage 1: Patients will be injected with a 1 ml emulsion containing GM-CSF in saline plus&#xD;
      Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.&#xD;
&#xD;
      In Stage 2: Patients will be randomized to receive an injection of one of the following in&#xD;
      skin adjacent to the melanoma biopsy scar:&#xD;
&#xD;
        1. 1 ml saline&#xD;
&#xD;
        2. GM-CSF in 1 ml saline&#xD;
&#xD;
        3. an emulsion of Montanide ISA-51 adjuvant and saline&#xD;
&#xD;
        4. an emulsion of GM-CSF in saline plus ml Montanide ISA-51 adjuvant. All vaccines will be&#xD;
           administered intradermally. After the injection, each patient will undergo wide excision&#xD;
           of the melanoma site, with or without sentinel node biopsy, as clinically indicated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of dendritic cells (total and mature) accumulating in the dermis after administration of the adjuvant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of the sentinel node occupied by dendritic cells (total and mature)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximal dendritic cell infiltration into the dermis</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first of 4 arms: injection: 1 ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GM-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Second of 4 arms: injection: specified dose of GM-CSF in 1 ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Third of 4 arms: injection: 0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fourth of 4 arms: injection: specified dose of GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF-in-adjuvant</intervention_name>
    <description>For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.&#xD;
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:&#xD;
1 ml saline&#xD;
specified dose of GM-CSF in 1 ml saline&#xD;
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline&#xD;
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant</description>
    <arm_group_label>GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montanide ISA-51</intervention_name>
    <description>For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.&#xD;
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:&#xD;
1 ml saline&#xD;
specified dose of GM-CSF in 1 ml saline&#xD;
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline&#xD;
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant</description>
    <arm_group_label>0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GM-CSF and Montanide ISA-51</intervention_name>
    <description>For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.&#xD;
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:&#xD;
1 ml saline&#xD;
specified dose of GM-CSF in 1 ml saline&#xD;
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline&#xD;
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant</description>
    <arm_group_label>GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.&#xD;
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:&#xD;
1 ml saline&#xD;
specified dose of GM-CSF in 1 ml saline&#xD;
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline&#xD;
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have been diagnosed, by histologic and clinical examination, with&#xD;
             resected AJCC stage I or II melanoma.&#xD;
&#xD;
          -  Patients who have any evidence of metastasis will not be eligible.&#xD;
&#xD;
          -  All patients must have:&#xD;
&#xD;
               1. Karnofsky performance of 80% or higher&#xD;
&#xD;
               2. ECOG performance status of 0 or 1&#xD;
&#xD;
               3. Ability and willingness to give informed consent&#xD;
&#xD;
          -  Laboratory parameters as follows:&#xD;
&#xD;
               1. ANC: 90% of lower limit of normal (LLN) to 120% of upper limit of normal (ULN)&#xD;
&#xD;
               2. Platelets: 100-500 x 103/uL&#xD;
&#xD;
               3. Hgb: 90% LLN to 120% ULN&#xD;
&#xD;
               4. Hepatic:&#xD;
&#xD;
                    1. AST, ALT, Bilirubin, and Alk phos within normal limits,&#xD;
&#xD;
                    2. LDH up to 1.2 x ULN&#xD;
&#xD;
               5. Renal:&#xD;
&#xD;
                    1. Creatinine up to 1.5 x ULN&#xD;
&#xD;
          -  Age 18-85 years at the time of study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are currently receiving cytotoxic chemotherapy, interferon, or radiation&#xD;
             or who have received this therapy within the preceding 12 weeks.&#xD;
&#xD;
          -  Patients with known or suspected allergies to any component of the vaccine.&#xD;
&#xD;
          -  Patients receiving the following medications at study entry or within the preceding 4&#xD;
             weeks are excluded:&#xD;
&#xD;
               -  Agents with putative immunomodulating activity (with the exception of&#xD;
                  non-steroidal anti-inflammatory agents),&#xD;
&#xD;
               -  Allergy desensitization injections,&#xD;
&#xD;
               -  Corticosteroids, administered parenterally or orally. Topical corticosteroids are&#xD;
                  acceptable.&#xD;
&#xD;
               -  Any growth factors, Interleukin-2 or other interleukins.&#xD;
&#xD;
          -  Pregnancy or the possibility of becoming pregnant during vaccine administration.&#xD;
             Female patients of child-bearing potential must have a negative pregnancy test&#xD;
             (urinary or serum beta-HCG) prior to administration of the injection.&#xD;
&#xD;
          -  Patients in whom there is a medical contraindication or potential problem in complying&#xD;
             with the requirements of the protocol, in the opinion of the investigator.&#xD;
&#xD;
          -  Patients classified according to the New York Heart Association classification as&#xD;
             having Class III or IV heart disease.&#xD;
&#xD;
          -  Patients with serious symptomatic active pulmonary disease, with pleural effusions, or&#xD;
             with a history of pulmonary edema.&#xD;
&#xD;
          -  Patients who have systemic autoimmune disease with visceral involvement.&#xD;
&#xD;
          -  Patients with clinically apparent skin infection or other clinically evident&#xD;
             inflammation involving the skin adjacent to the melanoma biopsy scar.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L Slingluff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Craig L Slingluff MD</name_title>
    <organization>University of Virginia</organization>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>adjuvant</keyword>
  <keyword>dendritic cells</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 19, 2010</submitted>
    <returned>May 19, 2010</returned>
    <submitted>June 24, 2010</submitted>
    <returned>July 19, 2010</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

